Unicycive Therapeutics Business Summary

Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for kidney disease, currently operating as a pre-revenue entity that derives value from its late-stage clinical pipeline. The company’s business model centers on the nephrology segment, specifically targeting the $1 billion-plus U.S. market for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Its lead asset, Oxylanthanum Carbonate (OLC), is a proprietary, non-chewable phosphate binder developed via the 505(b)(2) regulatory pathway to reduce pill burden and improve patient adherence. As of February 2026, Unicycive is preparing for potential commercialization following the FDA’s January 2026 acceptance of its resubmitted New Drug Application (NDA), which has been assigned a PDUFA target action date of June 29, 2026. The company competes directly with Akebia Therapeutics (Auryxia), CSL Vifor (Velphoro), and Ardelyx (Xphozah), positioning OLC as a superior alternative to the current standard of care due to its smaller tablet size and swallow-whole administration compared to chewable reference drugs like Fosrenol. The company was founded in 2016 by Dr. Shalabh Gupta, who serves as Chairman, President, and CEO, leveraging his background as a physician, equity researcher, and commercial strategist to lead the firm’s development efforts. The executive team includes Chief Financial Officer John Townsend and Executive Vice President of Pharmaceutical and Business Operations Dr. Pramod Gupta, an industry veteran with prior leadership experience at Spectrum Pharmaceuticals and Baxter Healthcare. Other key management figures include Dr. Guru Reddy, Vice President of Preclinical R&D, and Douglas Jermasek, EVP of Corporate Strategy. Unicycive’s board and investor base feature notable institutional support from firms such as Great Point Partners. As of early 2026, the company maintains a robust financial position with approximately $41.3 million in cash and equivalents, providing an operational runway into 2027 to fund the anticipated launch of OLC and the continued development of its secondary asset, UNI-494, for acute kidney injury.